Tuesday, 02 January 2024 12:17 GMT

Cohance Lifesciences Stock Tanks On ₹3,000 Crore Promoter Stake Sale


(MENAFN- AsiaNet News)

Shares of contract development and manufacturing organization (CDMO) firm Cohance Lifesciences fell as much as 6.2% to ₹906 on Thursday. The decline was due to reported block deals that saw around 3.39 crore shares, or 8.9% of the equity, worth around ₹3,073 crore change hands in early trade.

Promoter Jusmiral Holdings offloaded close to 34.1 million shares for around $350 million through block deals, according to a report by CNBC-TV18.

This came just a day after reports suggested Jusmiral was planning to pare up to 5.1% stake in the company, with the transaction size pegged at ₹1,756 crore at a floor price of ₹900 per share, a 6.9% discount to the stock's last close.

The report added that a 210-day lock-up period has been set for any additional share sales by the promoter. IIFL Capital acted as the book-running lead manager for the transaction.

As of the June quarter, Jusmiral Holdings held a 33.34% stake in Cohance Lifesciences, according to exchange data.

Year-to-date, the stock has declined by over 20%.

Technical View

On the monthly chart, the Cohance stock has been dropping to fresh lows consistently, with the relative strength index (RSI) indicating a sideways trend, noted SEBI-registered analyst Sunil Kotak.

The overall momentum remains bearish, with a strong supply zone at ₹960 - ₹975 and a demand zone at ₹860 - ₹880. 

The analyst noted that the stock is lagging behind the broader market and suggested it is best avoided for the time being.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

MENAFN18092025007385015968ID1110077838

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search